181 related articles for article (PubMed ID: 27506636)
1. Clinical-pathological features and treatment modalities associated with recurrence in DCIS and micro-invasive carcinoma: Who to treat more and who to treat less.
Toss A; Palazzo J; Berger A; Guiles F; Sendecki JA; Simone N; Anne R; Avery T; Jaslow R; Lazar M; Tsangaris T; Cristofanilli M
Breast; 2016 Oct; 29():223-30. PubMed ID: 27506636
[TBL] [Abstract][Full Text] [Related]
2. Molecular phenotypes of DCIS predict overall and invasive recurrence.
Williams KE; Barnes NLP; Cramer A; Johnson R; Cheema K; Morris J; Howe M; Bundred NJ
Ann Oncol; 2015 May; 26(5):1019-1025. PubMed ID: 25678586
[TBL] [Abstract][Full Text] [Related]
3. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
[TBL] [Abstract][Full Text] [Related]
4. Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E; Papadimitriou K; Tjalma W; Altintas S
Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
[TBL] [Abstract][Full Text] [Related]
5. The Relationships between HER2 Overexpression and DCIS Characteristics.
Di Cesare P; Pavesi L; Villani L; Battaglia A; Da Prada GA; Riccardi A; Frascaroli M
Breast J; 2017 May; 23(3):307-314. PubMed ID: 27943525
[TBL] [Abstract][Full Text] [Related]
6. Lobular carcinoma in situ (LCIS) of the breast: is long-term outcome similar to ductal carcinoma in situ (DCIS)? Analysis of 200 cases.
Cutuli B; De Lafontan B; Kirova Y; Auvray H; Tallet A; Avigdor S; Brunaud C; Delva C
Radiat Oncol; 2015 May; 10():110. PubMed ID: 25944033
[TBL] [Abstract][Full Text] [Related]
7. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
[TBL] [Abstract][Full Text] [Related]
8. Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast.
Barnes NL; Khavari S; Boland GP; Cramer A; Knox WF; Bundred NJ
Clin Cancer Res; 2005 Mar; 11(6):2163-8. PubMed ID: 15788662
[TBL] [Abstract][Full Text] [Related]
9. Metastatic invasive breast cancer recurrence following curative-intent therapy for ductal carcinoma in situ.
Al Mushawah F; Rastelli A; Pluard T; Margenthaler JA
J Surg Res; 2012 Mar; 173(1):10-5. PubMed ID: 21696764
[TBL] [Abstract][Full Text] [Related]
10. Improved outcomes of breast-conserving therapy for patients with ductal carcinoma in situ.
Halasz LM; Sreedhara M; Chen YH; Bellon JR; Punglia RS; Wong JS; Harris JR; Brock JE
Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):e581-6. PubMed ID: 22208975
[TBL] [Abstract][Full Text] [Related]
11. HER-2 overexpression is not associated with increased ipsilateral breast tumor recurrence in DCIS treated with breast-conserving surgery followed by radiotherapy.
Noh JM; Lee J; Choi DH; Cho EY; Huh SJ; Park W; Nam SJ; Lee JE; Kil WH
Breast; 2013 Oct; 22(5):894-7. PubMed ID: 23643805
[TBL] [Abstract][Full Text] [Related]
12. Women with Low-Risk DCIS Eligible for the LORIS Trial After Complete Surgical Excision: How Low Is Their Risk After Standard Therapy?
Pilewskie M; Olcese C; Patil S; Van Zee KJ
Ann Surg Oncol; 2016 Dec; 23(13):4253-4261. PubMed ID: 27766556
[TBL] [Abstract][Full Text] [Related]
13. [Combined surgery and radiotherapy in the treatment of ductal carcinoma in situ of the breast: preliminary results of the Hungarian multicenter prospective randomised study].
Polgár C; Orosz Z; Kahán Z; Gábor G; Jani N; Cserni G; Hadijev J; Kulka J; Sulyok Z; Boross G; Lázár G; László Z; Diczházi C; Udvarhelyi N; Szabó E; Péntek Z; Major T; Fodor J
Magy Onkol; 2008 Sep; 52(3):269-77. PubMed ID: 18845497
[TBL] [Abstract][Full Text] [Related]
14. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
15. Management of ductal carcinoma in situ in the modern era.
Khan A; Dumitru D; Catanuto G; Rocco N; Nava MB; Benson J
Minerva Chir; 2018 Jun; 73(3):303-313. PubMed ID: 29589680
[TBL] [Abstract][Full Text] [Related]
16. Expression of HER2neu in ductal carcinoma in situ is associated with local recurrence.
Han K; Nofech-Mozes S; Narod S; Hanna W; Vesprini D; Saskin R; Taylor C; Kong I; Paszat L; Rakovitch E
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):183-9. PubMed ID: 21958729
[TBL] [Abstract][Full Text] [Related]
17. Assessment of treatment for patients with primary ductal carcinoma in situ in the breast.
Fish EB; Chapman JA; Miller NA; Link MA; Fishell E; Wright B; McCready DR; Hiraki GY; Ross TM; Hanna WM; Lickley HL
Ann Surg Oncol; 1998 Dec; 5(8):724-32. PubMed ID: 9869520
[TBL] [Abstract][Full Text] [Related]
18. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
19. Controversies in the Treatment of Ductal Carcinoma in Situ.
Barrio AV; Van Zee KJ
Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
[TBL] [Abstract][Full Text] [Related]
20. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
